Sumitomo Mitsui Trust Group Inc. Sells 1,054,148 Shares of Pacific Biosciences of California, Inc. $PACB

Sumitomo Mitsui Trust Group Inc. decreased its position in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) by 17.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,955,567 shares of the biotechnology company’s stock after selling 1,054,148 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned approximately 1.59% of Pacific Biosciences of California worth $11,745,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in Pacific Biosciences of California in the 3rd quarter valued at about $38,000. Choreo LLC acquired a new stake in shares of Pacific Biosciences of California during the 3rd quarter worth approximately $27,000. Interchange Capital Partners LLC purchased a new stake in shares of Pacific Biosciences of California during the 3rd quarter valued at approximately $28,000. China Universal Asset Management Co. Ltd. raised its position in shares of Pacific Biosciences of California by 14.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 56,714 shares of the biotechnology company’s stock valued at $134,000 after buying an additional 7,282 shares during the period. Finally, AdvisorNet Financial Inc raised its position in shares of Pacific Biosciences of California by 17.2% during the 3rd quarter. AdvisorNet Financial Inc now owns 178,288 shares of the biotechnology company’s stock valued at $423,000 after buying an additional 26,166 shares during the period.

Wall Street Analyst Weigh In

A number of research analysts recently commented on PACB shares. Piper Sandler reiterated a “neutral” rating and issued a $3.00 price objective (up from $2.00) on shares of Pacific Biosciences of California in a report on Thursday. UBS Group assumed coverage on Pacific Biosciences of California in a research note on Wednesday, September 9th. They set a “neutral” rating and a $1.35 target price for the company. Weiss Ratings upgraded Pacific Biosciences of California from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, October 13th. Barclays upped their price target on Pacific Biosciences of California from $1.25 to $2.00 and gave the company an “underweight” rating in a research note on Thursday. Finally, Wall Street Zen upgraded Pacific Biosciences of California from a “sell” rating to a “hold” rating in a report on Saturday. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Pacific Biosciences of California currently has an average rating of “Reduce” and a consensus target price of $2.09.

Pacific Biosciences of California Trading Down 7.0%

Pacific Biosciences of California stock traded down $0.17 during trading on Friday, hitting $2.26. The company had a trading volume of 9,531,021 shares, compared to its average volume of 15,198,901. Pacific Biosciences of California, Inc. has a 1-year low of $1.07 and a 1-year high of $3.43. The company’s 50 day simple moving average is $1.93 and its 200-day simple moving average is $1.62. The stock has a market cap of $702.48 million, a price-to-earnings ratio of -5.38 and a beta of 2.21.

Pacific Biosciences of California (NASDAQ:PACB) last released its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. Pacific Biosciences of California had a negative return on equity of 5,752.12% and a negative net margin of 82.49%. The company had revenue of $40.56 million for the quarter, compared to analysts’ expectations of $39.31 million. As a group, analysts forecast that Pacific Biosciences of California, Inc. will post -0.52 earnings per share for the current fiscal year.

Insider Activity at Pacific Biosciences of California

In other Pacific Biosciences of California news, insider James R. Gibson II sold 661,815 shares of the stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $3.11, for a total transaction of $2,058,244.65. Following the sale, the insider directly owned 1,083,848 shares in the company, valued at $3,370,767.28. This represents a 37.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Van Oene sold 26,911 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1.13, for a total transaction of $30,409.43. Following the completion of the transaction, the insider directly owned 2,705,853 shares of the company’s stock, valued at $3,057,613.89. This represents a 0.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 3.70% of the company’s stock.

Pacific Biosciences of California News Summary

Here are the key news stories impacting Pacific Biosciences of California this week:

• Positive Sentiment: PacBio reported third-quarter revenue of $40.56 million, above the $39.31 million consensus, and a loss of $0.11 per share, narrower than the expected $0.13 loss. Coverage also highlighted clinical adoption and AI partnerships as sources of growth. Zacks Q3 results Q3 deep dive
• Positive Sentiment: Piper Sandler reaffirmed its Neutral rating but raised its price target to $3 from $2, indicating a more favorable valuation view. Piper Sandler rating
• Neutral Sentiment: The company announced CFO changes; the report provided no further detail on the transition’s expected impact. CFO changes
• Negative Sentiment: Management narrowed its 2026 revenue guidance to $155 million–$160 million. Analysts also pointed to falling gross margins and substantial cash burn, which raises concerns about the company’s financial position despite its target of cash-flow breakeven in 2028. Revenue guidance and breakeven target Q3 outlook analysis
• Negative Sentiment: Barclays lifted its price target to $2 from $1.25 but maintained an Underweight rating, signaling continued caution about the shares. Barclays rating

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc (NASDAQ: PACB) is a life sciences technology company that develops and supplies DNA sequencing systems, consumables and related software. The company is best known for its single-molecule, real-time (SMRT) sequencing technology, which produces highly accurate long-read data used to analyze complex genomes, structural variation, genetic disease and other biological information.

PacBio’s product portfolio includes the Revio long-read sequencing system, the Sequel II and Sequel IIe platforms, sequencing consumables and the associated data-analysis software.